The estimated Net Worth of Andrew T Drechsler is at least $4.32 million dollars as of 2 September 2020. Mr. Drechsler owns over 2,000 units of Provention Bio stock worth over $499,600 and over the last 19 years he sold PRVB stock worth over $0. In addition, he makes $3,818,660 as Chief Financial Officer at Provention Bio.
Andrew has made over 5 trades of the Provention Bio stock since 2016, according to the Form 4 filled with the SEC. Most recently he bought 2,000 units of PRVB stock worth $23,440 on 2 September 2020.
The largest trade he's ever made was exercising 45,000 units of Provention Bio stock on 14 November 2016 worth over $305,550. On average, Andrew trades about 3,641 units every 60 days since 2006. As of 2 September 2020 he still owns at least 20,000 units of Provention Bio stock.
You can see the complete history of Mr. Drechsler stock trades at the bottom of the page.
Andrew T. Drechsler serves as Chief Financial Officer of the Company. Mr. Drechsler joined Provention as Chief Financial Officer (CFO) in September 2017. Mr. Drechsler has over 20 years of financial and operational leadership experience in life sciences companies. Prior to Provention, Mr. Drechsler was most recently CFO of Insmed Incorporated from 2012 to 2017. Mr. Drechsler’s prior roles also include: CFO of VaxInnate Corporation, a privately held clinical-stage biotechnology company that developed vaccines for infectious diseases; CFO of publicly-traded Valera Pharmaceuticals where he completed an initial public offering; controller for Abbott Laboratories’ Point of Care Division, which was publicly-traded as i-STAT Corporation prior to being acquired by Abbott; controller of Biomatrix, Inc., which was publicly-traded prior to being acquired by Genzyme. Mr. Drechsler graduated magna cum laude from Villanova University with a BS in Accounting and received his certified public accountant license in New Jersey.
As the Chief Financial Officer of Provention Bio, the total compensation of Andrew Drechsler at Provention Bio is $3,818,660. There are 3 executives at Provention Bio getting paid more, with Ashleigh Palmer having the highest compensation of $3,959,460.
Andrew Drechsler is 48, he's been the Chief Financial Officer of Provention Bio since 2017. There are 12 older and 3 younger executives at Provention Bio. The oldest executive at Provention Bio, Inc. is Avery Catlin, 72, who is the Independent Director.
Andrew's mailing address filed with the SEC is C/O BAUDAX BIO, INC., 490 LAPP ROAD, MALVERN, PA, 19355.
Over the last 6 years, insiders at Provention Bio have traded over $81,606,241 worth of Provention Bio stock and bought 165,475 units worth $1,543,065 . The most active insiders traders include Capital (Master), L.P.Sessa..., Nancy Wysenski et Avery W Catlin. On average, Provention Bio executives and independent directors trade stock every 35 days with the average trade being worth of $3,621,900. The most recent stock trade was executed by Capital (Master), L.P.Sessa... on 14 April 2023, trading 2,190,549 units of PRVB stock currently worth $53,274,152.
Provention Bio, Inc., a clinical stage biopharmaceutical company, focuses on the development and commercialization of therapeutics and solutions to intercept and prevent immune-mediated diseases. Its products candidates include PRV-031 teplizumab and monoclonal antibodies (mAb) that is in Phase III clinical trial for the interception of type one diabetes (T1D); PRV-3279, which has completed Phase Ib clinical trial for the treatment of lupus; PRV-101, a coxsackie virus B (CVB) vaccine for the prevention of acute CVB infections and onset of T1D; and PRV-015, which is in phase IIb clinical trial for the treatment of gluten-free diet non-responding celiac disease. The company has a license and collaboration agreement with Amgen Inc. for PRV-015, a novel anti-IL-15 monoclonal antibody being developed for the treatment of gluten-free diet non-responsive celiac disease; and a strategic collaboration with Hangzhou Zhongmei Huadong Pharmaceutical Co., Ltd. to develop and commercialize PRV-3279, a bispecific antibody-based molecule targeting the B cell surface proteins CD32B and CD79B in Greater China. Provention Bio, Inc. was incorporated in 2016 and is headquartered in Red Bank, New Jersey.
Provention Bio executives and other stock owners filed with the SEC include: